I used my AI on this one!
CLOVER ORR — What Standard of Care Does Leronlimab Need to Beat?
I believe the **most appropriate benchmark for CLOVER is the approximately 6.1% ORR from the SUNLIGHT trial**, rather than the approximately 3% real-world ORR or the 19.4% result from a different study.
## 1. SUNLIGHT — approximately 6.1% ORR
This is the number I would consider the primary benchmark.
SUNLIGHT evaluated **trifluridine/tipiracil (TAS-102/Lonsurf) + bevacizumab** in refractory metastatic colorectal cancer.
That is particularly relevant because CLOVER is studying **leronlimab + TAS-102 + bevacizumab**.
SUNLIGHT produced approximately:
**ORR: 6.1%
Median PFS: 5.6 months
Median OS: 10.8 months**
Therefore, if CLOVER produces an ORR substantially above 6.1%, there is an argument that adding leronlimab is producing additional activity beyond what would historically be expected from the backbone.
## 2. The approximately 3% ORR
The roughly **3% ORR** is useful because real-world studies and pooled experiences with later-line treatment can produce response rates in the low single digits.
But I would NOT use 3% as the primary hurdle.
An FDA reviewer or sophisticated Big Pharma partner knows about SUNLIGHT. Therefore, I think they are much more likely to ask:
**"How does leronlimab + TAS-102 + bevacizumab compare with the approximately 6.1% ORR demonstrated by TAS-102 + bevacizumab in SUNLIGHT?"**
The 3% number helps demonstrate how difficult this patient population is to treat, but **6.1% is the more credible historical benchmark.**
## 3. What about the 19.4% ORR?
The **19.4% ORR** came from a small prospective Phase II study involving **fruquintinib + TAS-102**, with some patients also receiving SBRT radiation.
That study is interesting, but it is NOT an apples-to-apples comparison with CLOVER.
The regimen was different, the study was relatively small, and some patients received radiation.
Therefore, I would NOT say that FDA requires CLOVER to beat 19.4%.
However, it does provide an interesting reference point: **response rates approaching 20% can be achieved in later-line metastatic colorectal cancer when a combination is particularly active.**
# My CLOVER Scorecard
**6% or below ORR:**
Disappointing. Essentially SUNLIGHT territory.
**8–10% ORR:**
Evidence of activity, but probably not enough by itself to create major excitement.
**12–15% ORR:**
Clinically interesting. This would be roughly twice the SUNLIGHT response rate.
**15–20% ORR:**
Very meaningful. I believe this begins to enter serious **Big Pharma partnering territory**, assuming responses are confirmed and durable.
**20%+ ORR:**
Potentially exceptional for this refractory metastatic colorectal cancer population.
**25%+ ORR:**
Extremely difficult for the pharmaceutical industry to ignore if the responses are confirmed, durable, and accompanied by favorable PFS and safety.
# The Number I Am Watching
My personal target would be approximately:
**15–20%+ confirmed ORR in the 700 mg leronlimab group.**
For example, if there were approximately 30 evaluable patients:
**2 responders = 6.7% ORR
3 responders = 10.0%
4 responders = 13.3%
5 responders = 16.7%
6 responders = 20.0%
7 responders = 23.3%
8 responders = 26.7%**
This is why **5–6 confirmed responders out of approximately 30 evaluable patients** would get my attention.
That would produce approximately a **17–20% ORR**, versus approximately **6.1% historically in SUNLIGHT**.
# One Important Caveat
CLOVER does not have a contemporaneous TAS-102 + bevacizumab-only control arm.
Both randomized groups receive leronlimab with standard therapy, with the study comparing leronlimab dosing.
Consequently, simply producing 7% or 8% ORR probably would not be enough to conclude that leronlimab caused the improvement.
The stronger the ORR, however, the harder that historical-control argument becomes to dismiss.
And if a higher ORR is accompanied by:
**• longer PFS
• durable responses
• a favorable 700 mg dose-response
• major ctDNA reductions
• tumor shrinkage
• PD-L1 changes consistent with leronlimab's proposed mechanism
• acceptable safety**
then the total package becomes much more compelling.
# Bottom Line
If I had to reduce everything to three numbers:
**6.1% = the historical SOC benchmark CLOVER needs to clearly beat.**
**15% = where I start becoming quite interested.**
**20%+ = where I believe Big Pharma could become very interested, particularly if PFS, durability, ctDNA and the other biomarkers support the ORR result.**
The 19.4% number is therefore **not necessarily the hurdle**.
Instead, I would view **~20% ORR as the territory where CLOVER could begin looking genuinely exceptional rather than simply better than historical standard of care.**
CLOVER ORR — What Standard of Care Does Leronlimab Need to Beat?
I believe the **most appropriate benchmark for CLOVER is the approximately 6.1% ORR from the SUNLIGHT trial**, rather than the approximately 3% real-world ORR or the 19.4% result from a different study.
## 1. SUNLIGHT — approximately 6.1% ORR
This is the number I would consider the primary benchmark.
SUNLIGHT evaluated **trifluridine/tipiracil (TAS-102/Lonsurf) + bevacizumab** in refractory metastatic colorectal cancer.
That is particularly relevant because CLOVER is studying **leronlimab + TAS-102 + bevacizumab**.
SUNLIGHT produced approximately:
**ORR: 6.1%
Median PFS: 5.6 months
Median OS: 10.8 months**
Therefore, if CLOVER produces an ORR substantially above 6.1%, there is an argument that adding leronlimab is producing additional activity beyond what would historically be expected from the backbone.
## 2. The approximately 3% ORR
The roughly **3% ORR** is useful because real-world studies and pooled experiences with later-line treatment can produce response rates in the low single digits.
But I would NOT use 3% as the primary hurdle.
An FDA reviewer or sophisticated Big Pharma partner knows about SUNLIGHT. Therefore, I think they are much more likely to ask:
**"How does leronlimab + TAS-102 + bevacizumab compare with the approximately 6.1% ORR demonstrated by TAS-102 + bevacizumab in SUNLIGHT?"**
The 3% number helps demonstrate how difficult this patient population is to treat, but **6.1% is the more credible historical benchmark.**
## 3. What about the 19.4% ORR?
The **19.4% ORR** came from a small prospective Phase II study involving **fruquintinib + TAS-102**, with some patients also receiving SBRT radiation.
That study is interesting, but it is NOT an apples-to-apples comparison with CLOVER.
The regimen was different, the study was relatively small, and some patients received radiation.
Therefore, I would NOT say that FDA requires CLOVER to beat 19.4%.
However, it does provide an interesting reference point: **response rates approaching 20% can be achieved in later-line metastatic colorectal cancer when a combination is particularly active.**
# My CLOVER Scorecard
**6% or below ORR:**
Disappointing. Essentially SUNLIGHT territory.
**8–10% ORR:**
Evidence of activity, but probably not enough by itself to create major excitement.
**12–15% ORR:**
Clinically interesting. This would be roughly twice the SUNLIGHT response rate.
**15–20% ORR:**
Very meaningful. I believe this begins to enter serious **Big Pharma partnering territory**, assuming responses are confirmed and durable.
**20%+ ORR:**
Potentially exceptional for this refractory metastatic colorectal cancer population.
**25%+ ORR:**
Extremely difficult for the pharmaceutical industry to ignore if the responses are confirmed, durable, and accompanied by favorable PFS and safety.
# The Number I Am Watching
My personal target would be approximately:
**15–20%+ confirmed ORR in the 700 mg leronlimab group.**
For example, if there were approximately 30 evaluable patients:
**2 responders = 6.7% ORR
3 responders = 10.0%
4 responders = 13.3%
5 responders = 16.7%
6 responders = 20.0%
7 responders = 23.3%
8 responders = 26.7%**
This is why **5–6 confirmed responders out of approximately 30 evaluable patients** would get my attention.
That would produce approximately a **17–20% ORR**, versus approximately **6.1% historically in SUNLIGHT**.
# One Important Caveat
CLOVER does not have a contemporaneous TAS-102 + bevacizumab-only control arm.
Both randomized groups receive leronlimab with standard therapy, with the study comparing leronlimab dosing.
Consequently, simply producing 7% or 8% ORR probably would not be enough to conclude that leronlimab caused the improvement.
The stronger the ORR, however, the harder that historical-control argument becomes to dismiss.
And if a higher ORR is accompanied by:
**• longer PFS
• durable responses
• a favorable 700 mg dose-response
• major ctDNA reductions
• tumor shrinkage
• PD-L1 changes consistent with leronlimab's proposed mechanism
• acceptable safety**
then the total package becomes much more compelling.
# Bottom Line
If I had to reduce everything to three numbers:
**6.1% = the historical SOC benchmark CLOVER needs to clearly beat.**
**15% = where I start becoming quite interested.**
**20%+ = where I believe Big Pharma could become very interested, particularly if PFS, durability, ctDNA and the other biomarkers support the ORR result.**
The 19.4% number is therefore **not necessarily the hurdle**.
Instead, I would view **~20% ORR as the territory where CLOVER could begin looking genuinely exceptional rather than simply better than historical standard of care.**
5
